Skip to main content
SpringerLink
Log in

Early treatment response to sorafenib for rabbit VX2 orthotic liver tumors: evaluation by quantitative contrast-enhanced ultrasound

  • Research Article
  • Published:
Tumor Biology

Abstract

The aim of our study was to investigate the application of contrast-enhanced ultrasound (CEUS) and its quantification analysis for the prediction of early treatment response of sorafenib on rabbit VX2 liver tumor model. Rabbits were implanted VX2 tumor mass to establish a liver tumor model. Fourteen days after tumor implantation, rabbits presented with single liver tumor were randomly divided into two groups. Rabbits in treatment group were given by gavage once a day for 14 days with sorafenib suspension at a dose of 30 mg/kg, whereas rabbits in control group were given saline by gavage of the same volume. CEUS was performed before treatment and 3, 7, 14 days after treatment for the analysis of tumor size, enhancement pattern, and necrosis range. The time intensity curve (TIC) was used to obtain quantitative parameters of enhancement patterns. Before sorafenib administration, tumor volumes ranged from 0.24 to 0.75 cm3 (mean 0.49 ± 0.18 cm3) in treatment group and 0.24 to 0.44 cm3 (mean 0.30 ± 0.12 cm3) in control group. The dynamic enhancement patterns of tumors were homogeneous hyper-enhancement (n = 8), heterogeneous hyper-enhancement (n = 4), and peripheral rim-like enhancement (n = 2). All tumors of the treatment group presented with peripheral rim-like enhancement with large necrotic area after sorafenib administration, whereas tumors of the control group showed heterogeneous hyper-enhancement (n = 5) and peripheral rim-like enhancement (n = 2). There was a significant difference in area under the curve (AUC) before and after sorafenib treatment (P = 0.045). CEUS may be of value in the evaluation of early therapeutic response after sorafenib administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology. 2009;49(2):658–64.

    Article  Google Scholar 

  2. Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol. 2010;80(5):550–60.

    Article  CAS  PubMed  Google Scholar 

  3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.

    Article  CAS  PubMed  Google Scholar 

  4. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57(4):821–9.

    Article  CAS  PubMed  Google Scholar 

  5. Sun S, Schiller JH. Angiogenesis inhibitors in the treatment of lung cancer. Crit Rev Oncol Hematol. 2007;62(2):93–104.

    Article  PubMed  Google Scholar 

  6. Cyran CC, Schwarz B, Paprottka PM, Sourbron S, von Einem JC, Dietrich O, et al. In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media. Cancer Imaging. 2013;13(4):557–66.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Goggi JL, Bejot R, Moonshi SS, Bhakoo KK. Stratification of 18 F-labeled PET imaging agents for the assessment of antiangiogenic therapy responses in tumors. J Nucl Med. 2013;54(9):1630–6.

    Article  CAS  PubMed  Google Scholar 

  8. Anderson H, Price P, Blomley M, Leach MO, Workman P. Measuring changes in human tumour vasculature in response to therapy using functional imaging techniques. Br J Cancer. 2001;85(8):1085–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Rouffiac V, Bouquet C, Lassau N, Opolon P, Koscielny S, Peronneau P, et al. Validation of a new method for quantifying in vivo murine tumor necrosis by sonography. Investig Radiol. 2004;39(6):350–6.

    Article  Google Scholar 

  10. Lamuraglia M, Bridal SL, Santin M, Izzi G, Rixe O, Paradiso A, et al. Clinical relevance of contrast-enhanced ultrasound in monitoring anti-angiogenic therapy of cancer: current status and perspectives. Crit Rev Oncol Hematol. 2010;73(3):202–12.

    Article  PubMed  Google Scholar 

  11. Luo W, Zhou X, Zheng X, He G, Yu M, Li Q, et al. Role of sonography for implantation and sequential evaluation of a VX2 rabbit liver tumor model. J Ultrasound Med. 2010;29(1):51–60.

    Article  PubMed  Google Scholar 

  12. Zhou P, Zhou P, He W, Wang LH, Li XH, Tian SM, et al. The influence of blood supply on high intensity focused ultrasound: a preliminary study on rabbit hepatic VX2 tumors of different ages. Acad Radiol. 2012;19(1):40–7.

    Article  PubMed  Google Scholar 

  13. Yoshida K, Hirokawa T, Moriyasu F, Liu L, Liu GJ, Yamada M, et al. Arterial-phase contrast-enhanced ultrasonography for evaluating anti-angiogenesis treatment: a pilot study. World J Gastroenterol. 2011;17(8):1045–50.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Zhang YJ, Chen MS, Li JQ, Zhang YQ, Zhong C, Liang HH. Radiofrequency ablation combined with ethanol injection for liver cancer treatment—an experimental study. Ai Zheng. 2006;25(9):1092–6.

    PubMed  Google Scholar 

  15. Lin WY, Chen J, Lin Y, Han K. Implantation of VX2 carcinoma into the liver of rabbits: a comparison of three direct-injection methods. J Vet Med Sci. 2002;64(7):649–52.

    Article  PubMed  Google Scholar 

  16. He W, Wang W, Zhou P, Wang YX, Zhou P, Li RZ, et al. Enhanced ablation of high intensity focused ultrasound cardiovasc with microbbles: an experimental study on rabbit hepatic VX2 tumors. Cardiovasc Intervent Radiol. 2011;34(5):1050–7.

    Article  CAS  PubMed  Google Scholar 

  17. Sugimoto K, Moriyasu F, Saito K, Rognin N, Kamiyama N, Furuichi Y, et al. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US. Liver Int. 2013;33(4):605–15.

    Article  CAS  PubMed  Google Scholar 

  18. Frampas E, Lassau N, Zappa M, Vullierme MP, Koscielny S, Vilgrain V. Advanced hepatocellular carcinoma: early evaluation of response to targeted therapy and prognostic value of perfusion CT and dynamic contrast enhanced-ultrasound. Preliminary results. Eur J Radiol. 2013;82(5):e205–11.

    Article  PubMed  Google Scholar 

  19. Shiozawa K, Watanabe M, Kikuchi Y, Kudo T, Maruyama K, Sumino Y. Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study. World J Gastroenterol. 2012;18(40):5753–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Wang Z, Yang G, Nie P, Fu J, Wang X, Liu D. Dynamical observation on biological progression of VX2 liver tumors to identify the optimal time for intervention in animal models. PLoS One. 2013;8(8):e74327.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This research is supported by the national Nature Science Foundation of China (81371577)

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, 200032, China

    Wen-Tao Kong, Hai-Xia Yuan, Wen-Ping Wang, Yang Tang & Xiao-Long Zhang

  2. Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China

    Hao Cai

Authors
  1. Wen-Tao Kong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hai-Xia Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hao Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wen-Ping Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yang Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiao-Long Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wen-Ping Wang.

Additional information

Hai-Xia Yuan contributed equally to this work and should be considered co-first author.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kong, WT., Yuan, HX., Cai, H. et al. Early treatment response to sorafenib for rabbit VX2 orthotic liver tumors: evaluation by quantitative contrast-enhanced ultrasound. Tumor Biol. 36, 2593–2599 (2015). https://doi.org/10.1007/s13277-014-2877-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2877-x

Keywords

Search

Navigation